BBIO:NSD-BridgeBio Pharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.70

Change

-0.64 (-6.85)%

Market Cap

USD 1.36B

Volume

1.80M

Avg Analyst Target

USD 20.86 (+139.74%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BBIO Stock Forecast & Price:
Based on the BridgeBio Pharma Inc stock forecasts from 5 analysts, the average analyst target price for BridgeBio Pharma Inc is USD 20.86 over the next 12 months. BridgeBio Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BridgeBio Pharma Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, BridgeBio Pharma Inc’s stock price was USD 8.70. BridgeBio Pharma Inc’s stock price has changed by +9.16% over the past week, +20.17% over the past month and -85.35% over the last year.

About BridgeBio Pharma Inc (BBIO:NSD)

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in deve ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-11.15 (-3.88%)

USD74.82B 30.88 20.19
REGN Regeneron Pharmaceuticals Inc

-7.98 (-1.32%)

USD67.28B 8.71 6.35
MRNA Moderna Inc

-3.17 (-2.18%)

USD57.82B 4.27 2.57
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.74 (+0.42%)

USD33.01B 55.02 44.86
BNTX BioNTech SE

-3.89 (-2.71%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.27 (-0.63%)

USD29.12B 31.56 15.41
GMAB Genmab AS

-0.95 (-2.93%)

USD21.17B 63.61 5.25
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

-9.00 (-2.41%)

USD19.77B N/A N/A

ETFs Containing BBIO

Symbol Name Weight Mer Price(Change) Market Cap
IBBJ Defiance Nasdaq Junior Bi.. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.84% 46% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.84% 46% F 27% F
Trailing 12 Months  
Capital Gain -85.53% 15% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.53% 15% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.20% 66% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.20% 66% D 73% C
Risk Return Profile  
Volatility (Standard Deviation) 64.58% 43% F 22% F
Risk Adjusted Return 26.63% 69% D+ 58% F
Market Capitalization 1.36B 88% B+ 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 123.68 1% F 1% F
Price / Cash Flow Ratio -2.74 51% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,789.67% 1% F 1% F
Return on Invested Capital -84.27% 27% F 12% F
Return on Assets -36.73% 28% F 9% F
Debt to Equity Ratio -195.75% 97% A+ 95% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.21 24% F 12% F
Short Percent 24.27% 4% F 7% F
Beta 1.21 59% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.